Document Detail


Statins in the treatment of central nervous system autoimmune disease.
MedLine Citation:
PMID:  16860400     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.
Authors:
Martin S Weber; Sawsan Youssef; Shannon E Dunn; Thomas Prod'homme; Oliver Neuhaus; Olaf Stuve; John Greenwood; Lawrence Steinman; Scott S Zamvil
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2006-07-24
Journal Detail:
Title:  Journal of neuroimmunology     Volume:  178     ISSN:  0165-5728     ISO Abbreviation:  J. Neuroimmunol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-05     Completed Date:  2006-11-14     Revised Date:  2011-11-03    
Medline Journal Info:
Nlm Unique ID:  8109498     Medline TA:  J Neuroimmunol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  140-8     Citation Subset:  IM    
Affiliation:
Department of Neurology and Program in Immunology, University of California, San Francisco, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigen Presentation / drug effects
Autoimmune Diseases of the Nervous System / drug therapy*
Brain / drug effects,  immunology
Clinical Trials as Topic
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Signal Transduction / immunology*
Spinal Cord / drug effects,  immunology
T-Lymphocytes / drug effects
Grant Support
ID/Acronym/Agency:
675//Multiple Sclerosis Society; R01 AI05709/AI/NIAID NIH HHS; //Wellcome Trust
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The validation of personal health questionnaire amongst people of Pakistani family origin living in ...
Next Document:  Comparison of available methods to elute serum from dried blood spot samples for measles serology.